MCL5 MARiT Study

• Research type

  Research Study

• Full title

  Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 Years

• IRAS ID

  81050

• Contact name

  Stephen Robinson

• Sponsor organisation

  PLymouth Hospitals NHS Trust

• Eudract number

  2011-004039-30

• ISRCTN Number

  N/A

• Research summary

  Mantle cell lymphoma (MCL) is an incurable malignancy with a median survival of 5 years. Induction chemotherapy followed by consolidation autologous stem cell transplantation (ASCT) has been shown to prolong disease free survival and has become a standard of care in younger patients. However, a continual pattern of relapse is observed following such therapy demonstrating the need to improve front line therapy. The combination of maxi-CHOP with high dose Ara-C (8-12gm/m2) and Rituximab has recently been shown to improve the response rates compared to CHOP induction alone. However, patients show a continuous pattern of relapse with this approach. Other groups have also demonstrated the efficacy of high dose ara-C based induction regimens. Rituximab has also been shown to improve response rates in prospective studies. There is therefore a strong rationale to explore the combination of high dose Ara-C and Rituximab as an induction therapy prior to ASCT.

• REC name

  London - South East Research Ethics Committee

• REC reference

  12/LO/0211

• Date of REC Opinion

  20 Feb 2012

• REC opinion

  Favourable Opinion